Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9008)	8/26/2003 10:43:37 AM
From: Icebrg	Read Replies (1) \| Respond to of 52153

<CTIC> Thank you, Peter. I bought some today. I think their approach looks reasonable. Further, CTIC and Novuspharma should make a good strategic fit with both companies complementing each other with regard to competencies and geography. Erik

To: Biomaven who wrote (9008)	8/26/2003 5:43:15 PM
From: Icebrg	Read Replies (1) \| Respond to of 52153

<CTIC> >>I figure with an approved drug with about $30m sales, a shot at $100m+ sales if they get a label expansion>> Considering the level of activity in the clinics, that might not be impossible. Clinical Trials Forty-two TRISENOX® clinical trials studying the drug alone and in combination with other therapies are ongoing, are planned to begin in the near future, or were recently completed. Twelve of these 42 trials are being done under the sponsorship of the National Cancer Institute (NCI) in the United States, under a Cooperative Research and Development Agreement (CRADA) with us. Preliminary data from ongoing clinical trials have shown encouraging responses in patients with multiple myeloma, MDS, CML, lymphoma, prostate cancer, and neuroblastoma. Ten of these studies are being conducted in patients with various solid tumors for which preclinical studies have shown potential activity of TRISENOX®. In addition to the 42 current trials, 4 trials in various solid tumors have been approved in concept by the NCI for inclusion in the CRADA program, and 13 trials are planned by independent investigators for the coming year.